Moderna and Catalent will produce Moderna Coronavirus vaccine at Catalent Biological Plant in Bloomington, Indiana. Production will be 24/7, and partners plan to deliver 100 million doses of the vaccine to the U.S. market as early as Q3 2020. Catalent will also provide this vaccine for clinical trials, which are expected to start Phase 3 in July.